Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMARCA2 | P51531 | 13/20 | 0.48 |
| ▸ | SMARCA4 | P51532 | 13/20 | 0.48 |
| ▸ | PBRM1 | Q86U86 | 14/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29943157 | 0.92 | SMARCA2 (0.53) | SMARCA2SMARCA4PBRM1BRD4NR1I2 | |
| SCHEMBL30797027 | 0.92 | SMARCA2 (0.53) | SMARCA2SMARCA4PBRM1BRD4NR1I2 | |
| SCHEMBL23301459 | 0.92 | SMARCA2 (0.53) | SMARCA2SMARCA4PBRM1BRD4NR1I2 | |
| SCHEMBL29942615 | 0.89 | CHRM4 (0.42) | CHRM4 | |
| SCHEMBL29910839 | 0.89 | SMARCA2 (0.46) | SMARCA2SMARCA4PBRM1BRD4CHRM4 | |
| SCHEMBL23301166 | 0.89 | SMARCA2 (0.46) | SMARCA2SMARCA4PBRM1BRD4CHRM4 | |
| SCHEMBL23301401 | 0.86 | SMARCA2 (0.46) | SMARCA2SMARCA4PBRM1CHRM4 | |
| SCHEMBL29910593 | 0.86 | SMARCA2 (0.46) | SMARCA2SMARCA4PBRM1CHRM4 | |
| SCHEMBL23303238 | 0.83 | SMARCA2 (0.51) | SMARCA2SMARCA4PBRM1BRD4NR1I2 | |
| SCHEMBL29910641 | 0.83 | SMARCA2 (0.51) | SMARCA2SMARCA4PBRM1BRD4NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4051674-A1 | BIFUNCTIONAL COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2022-09-07 | — | — | EP | disclosed |